venlafaxine extended release / Generic mfg. - LARVOL DELTA

Pharmacological Re-Optimization With Venlafaxine in Two Elderly Patients With Severe Major Depressive Disorder Considered for Electroconvulsive Therapy: A Two-Patient Case Report. (PubMed, Clin Case Rep) - "Case 2 was a woman in her late 80s with prior clipping of an unruptured middle cerebral artery aneurysm whose symptoms worsened despite outpatient mirtazapine and risperidone with the addition of duloxetine. In both cases, duloxetine was cross-tapered to venlafaxine extended-release while mirtazapine was continued, and venlafaxine ER was titrated to 150 mg/day as a closely monitored, time-limited pharmacological re-optimization step during ECT preparation...Appetite and oral intake improved, and planned ECT was canceled. These cases highlight the potential value of individualized pharmacological re-evaluation, including SNRI switching, even when ECT is being considered."

Journal • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Vascular Neurology

The role of venlafaxine in the modern treatment of anxiety disorders: a critical update and expert clinical perspectives. (PubMed, Riv Psichiatr) - "Extended-release (XR) venlafaxine, a serotonin-noradrenaline reuptake inhibitor, has emerged as a first-line pharmacological option, endorsed by international guidelines for generalized anxiety disorder, panic disorder, and social anxiety disorder. Given the established role of XR venlafaxine as a key therapeutic option in the pharmacological management of anxiety disorders, and acknowledging the impact of CYP2D6 metabolic variability on its efficacy and tolerability, pharmacogenetic testing could be recommended to optimize treatment personalization. It holds particular promise for patients with comorbid or treatment-resistant profiles, offering measurable benefits in quality of life, functional outcomes, and long-term disease management."

Journal • Review • CNS Disorders • Depression • General Anxiety Disorder • Immunology • Major Depressive Disorder • Mood Disorders • Pain • Psychiatry • Social Anxiety Disorder

An open-label, long-term extension, multicenter study to evaluate the safety and efficacy of venlafaxine extended release in Japanese outpatients with generalized anxiety disorder. (PubMed, PCN Rep) - "Similar improvements were also observed in CGI-S and CGI-I scores, suggesting the effectiveness of venlafaxine ER with long-term use. The overall safety profile with long-term use of venlafaxine ER was consistent with the one previously observed, confirming the safety of long-term use of venlafaxine ER in Japanese adult patients with GAD."

Clinical • Journal • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry • Suicidal Ideation

A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD (clinicaltrials.gov) - P4 | N=304 | Active, not recruiting | Sponsor: University of Pennsylvania | Trial completion date: Jul 2026 ➔ Nov 2026 | Trial primary completion date: Jul 2026 ➔ Nov 2026

Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Toward Precision Psychiatry: Using Clinical and Pharmacokinetic Data to Increase Antidepressant Dose or Change Treatment in Late-Life Depression. (PubMed, J Clin Psychopharmacol) - "Our methods can guide future studies combining clinical and biomarker data to address applied pharmacological questions relevant to day-to-day practice."

Journal • PK/PD data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Acute suppurative thyroiditis presenting as tonsillitis in a patient with depression, can venlafaxine be the culprit?, a case report. (AACE 2026) - "He initially visited urgent care 2 weeks prior for malaise and sore throat being prescribed augmentin for 10 days and prednisone 20 mg for 3 days to treat tonsillitis. Based on improvement with antibiotics and NSAIDS, the culprit in this case was most likely bacterial; however, the FDA categorizes thyroiditis under endocrine system adverse reactions as a "rare” event in patients taking venlafaxine XR. They also include goiter, hyperthyroidism,"

Case report • Clinical • CNS Disorders • Depression • Endocrine Disorders • Infectious Disease • Mood Disorders • Otorhinolaryngology • Psychiatry

Functional Pharmacobezoar and Bowel Ischemia Requiring Hemicolectomy Complicating Extended-Release Carbamazepine-Venlafaxine Overdose. (PubMed, Crit Care Explor) - "Carbamazepine-venlafaxine ER overdose with retained pill fragments can cause a variety of complications including prolonged toxicity. Rebounding drug concentration following enhanced elimination should trigger an investigation for gastrointestinal sequestration and prompt surgical consultation."

Journal • Cardiovascular • Ventricular Tachycardia

NCI-2018-01055: Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy (clinicaltrials.gov) - P2 | N=62 | Completed | Sponsor: Roswell Park Cancer Institute | Phase classification: P=N/A ➔ P2

HEOR • Phase classification • Head and Neck Cancer • Oncology • Pain • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer

Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis (clinicaltrials.gov) - P2 | N=70 | Not yet recruiting | Sponsor: Ain Shams University

New P2 trial • Congestive Heart Failure • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A Randomized Controlled Trial of Desvenlafaxine versus Venlafaxine in the Treatment of SSRI-Resistant Depression (ChiCTR) - P4 | N=80 | Not yet recruiting | Sponsor: Shandong Mental Health Center; Shandong Mental Health Center

New P4 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Response to "Clinical relevance of venlafaxine ER for generalized anxiety disorder". (PubMed, Psychiatry Clin Neurosci) - "This article relates to clinical relevance of venlafaxine ER for generalized anxiety disorder."

Journal • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Patient treatment preference as a predictor of clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and nonresponders with treatment-resistant depression (ASCERTAIN-TRD). (PubMed, Int Clin Psychopharmacol) - P4 | "This is a secondary analysis investigating the relationship between treatment preference and response to treatment in the antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) trial (NCT02977299) comparing three treatment arms [aripiprazole augmentation, repetitive transcranial magnetic stimulation (rTMS) augmentation, switching to venlafaxine XR or duloxetine] in MDD patients with treatment-resistant depression (TRD) who are currently on ongoing, stable, and adequate antidepressant therapy. In the total population, participants' preferences did not affect their response to treatment, and the change in MADRS score was similar among patients who received their preferred treatment, had no preference, or received treatment against their preference (P = 0.49). These results indicate that patient preference is not a significant factor that predisposes to optimal treatment outcomes."

Clinical data • HEOR • Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Venlafaxine-induced serotonin syndrome causing bilateral cerebral strokes: a case report. (PubMed, Front Stroke) - "A 21-year-old Caucasian woman was admitted to our neurologic intermediate care unit after attempting suicide by ingesting an estimated 15 g venlafaxine (Trevilor retard®), adding up to a serum concentration of approximately 17,943 μg/l. Furthermore, we aim to increase awareness of hypoglycemia and epileptic seizures as complications of venlafaxine intoxication. In addition, we demonstrate important pitfalls in the diagnostic procedure and propose a treatment regimen for the underlying serotonin syndrome."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Hypoglycemia • Ischemic stroke • Psychiatry

CEASE-GAD: Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder (clinicaltrials.gov) - P2 | N=216 | Recruiting | Sponsor: Anhui Medical University

New P2 trial • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD (clinicaltrials.gov) - P4 | N=302 | Active, not recruiting | Sponsor: University of Pennsylvania | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Multiple Ascending Dose Phase 1 Study of ALA-3000 (clinicaltrials.gov) - P1 | N=37 | Completed | Sponsor: Alar Pharmaceuticals Inc. | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Mood Disorders • Psychiatry

Clinical relevance of venlafaxine ER for generalized anxiety disorder. (PubMed, Psychiatry Clin Neurosci) - "Methodological factors-including the exclusion of placebo responders, the inclusion of participants with comorbid depressive disorders, and a higher rate of discontinuation due to adverse events-further diminish the clinical significance of the findings. Overall, although venlafaxine achieved statistical efficacy, it may lack a clinically meaningful risk-benefit balance."

Clinical • Journal • CNS Disorders • Depression • General Anxiety Disorder • Mood Disorders • Psychiatry

Zydus Lifesciences has received approval from the National Medical Products Administration (NMPA), China for Venlafaxine Extended-Release (ER) Capsules, 75 mg and 150 mg. (Business Standard) - "Venlafaxine ER Capsules are indicated for the treatment of Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD)."

China approval • Depression • General Anxiety Disorder • Major Depressive Disorder • Social Anxiety Disorder

Evaluation of the Efficacy and Safety of Crisugabalin Capsules versus Placebo and Venlafaxine Extended-Release (XR) Capsules in Chinese Patients with Generalized Anxiety Disorder: A Prospective, Multicenter, Randomized, Double-Blind, Double-Dummy, Active- and Placebo-Controlled Clinical Trial (CEASE-GAD). (ChiCTR) - P4 | N=216 | Not yet recruiting | Sponsor: The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university

New P4 trial • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Multiple Ascending Dose Phase 1 Study of ALA-3000 (clinicaltrials.gov) - P1 | N=44 | Active, not recruiting | Sponsor: Alar Pharmaceuticals Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Depression • Mood Disorders • Psychiatry

A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release in Japanese patients with generalized anxiety disorder. (PubMed, Psychiatry Clin Neurosci) - "Venlafaxine ER has a favorable benefit-risk profile in adult Japanese patients with GAD, indicating its potential to improve GAD symptoms as well as patients' function and exert superior anxiolytic effects over placebo without any new safety concern."

Clinical • Journal • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Nonresponders With Treatment Resistant Depression (ASCERTAIN-TRD): Effect of Aripiprazole or Repetitive Transcranial Magnetic Stimulation Augmentation Versus Switching to the Antidepressant Venlafaxine on Quality of Life. (PubMed, J Clin Psychiatry) - P4 | "Objective: This study compared the effects of augmenting antidepressants with aripiprazole or repetitive transcranial magnetic stimulation (rTMS) versus switching to venlafaxine XR/duloxetine on quality of life (QoL) among patients with treatment resistant depression (TRD). However, a much smaller than expected sample size for the rTMS group may explain the lack of statistical significance rendering the latter finding of indeterminate nature. Trial Registration: ClinicalTrials.gov identifier: NCT02977299."

HEOR • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

MDMA-assisted therapy and current treatment options for chronic, treatment-resistant, moderate or higher severity post-traumatic stress disorder: Systematic literature review. (PubMed, PLoS One) - "This systematic review suggests current treatments for PTSD are associated with heterogeneous evidence and the majority do not demonstrate sustained effects. Results from MDMA-AT showed consistent improvements in CAPS, BDI and LOD."

Journal • Review • CNS Disorders • Depression • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry

Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). (PubMed, J Affect Disord) - "Although rTMS augmentation did not reach a statistically significant difference in subjective cognitive improvement, it showed a larger effect size compared to aripiprazole augmentation. Our findings signal that rTMS augmentation may offer a well-tolerated strategy for improving cognition in TRD."

HEOR • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer (clinicaltrials.gov) - P3 | N=20 | Suspended | Sponsor: New York State Psychiatric Institute | Active, not recruiting ➔ Suspended

Trial suspension • Breast Cancer • CNS Disorders • Depression • Major Depressive Disorder • Oncology • Psychiatry • Solid Tumor